Aptevo Therapeutics (APVO) Other financing activities (2015 - 2023)

Aptevo Therapeutics (APVO) posted Other financing activities of -$98000.0 for Q4 2023, down 112.25% sequentially from $800000.0 in Q4 2021.

Aptevo Therapeutics (APVO) Other financing activities (2015 - 2023) Analysis & Trends

Aptevo Therapeutics has reported Other financing activities for 7 years, with the latest figure at -$98000.0 in Q4 2023.

Quarterly Other financing activities changed N/A year-over-year to -$98000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $417000.0 (changed N/A YoY) and the FY2025 annual result came in at $557000.0, down 89.99% from the prior year.
Other financing activities eased to -$98000.0 in Q4 2023 per APVO's latest filing, from $800000.0 in the prior quarter.
Over five years, Other financing activities peaked at $21.2 million in Q4 2020 and troughed at -$785000.0 in Q3 2021.
A 3-year average of $3.7 million and a median of $500000.0 in 2021 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 96.23% in 2021, down 96.23% in 2021.
Over 3 years, Other financing activities stood at $21.2 million in 2020, then sank by 96.23% to $800000.0 in 2021, then plunged by 112.25% to -$98000.0 in 2023.
According to Business Quant data, Other financing activities over the past three periods registered -$98000.0, $800000.0, and -$785000.0 for Q4 2023, Q4 2021, and Q3 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Aptevo Therapeutics	3.18 Mn	-6.61 Mn	-

Download Data